BioMarin Pharmaceutical (NASDAQ:BMRN) reports Q3 2026 in line with expectations but full-year sales guidance misses expectations
BioMarin Pharmaceutical reported Q3 2026 revenue of $1.02 billion, matching estimates, with adjusted EPS of $0.23, beating estimates. However, the company lowered its full-year revenue and EPS guidance, citing lower margins and free cash flow.
How this was made
The 30-second read
Why it matters
A guidance miss typically drives the largest estimate revisions, even when quarterly metrics beat, because it changes the forward earnings power and cash-flow outlook.
Market read
Traders can update models immediately using the stated midpoint guidance changes and reassess positioning ahead of subsequent biotech earnings/guidance cycles.
What to watch
Free cash flow margin fell sharply year over year, so investors may focus on working-capital or cost timing; traders should watch whether the guidance cut is tied to specific pipeline/commercial drivers not detailed here.
Background
The piece frames BioMarin’s Q3 as broadly in-line on revenue but highlights a full-year guidance reset lower for both revenue and adjusted EPS.
Ticker impact
BioMarin reported Q3 results in line but cut full-year revenue guidance to $3.85B midpoint and lowered adjusted EPS guidance to $2.95.
Likely downside pressure as the market reprices full-year revenue and EPS expectations after the guidance cut.
The article explicitly states full-year revenue guidance was lowered versus expectations and adjusted EPS guidance dropped 41% at the midpoint, which typically drives valuation and positioning more than an in-line quarter.
Market effects
Biotech/rare disease peers may see read-across on demand durability and margin sustainability if investors generalize the guidance caution.
Limited, primarily US large-cap biotech sentiment.
Low, company-specific guidance update with no stated global macro catalyst.
Counterpoint
The quarter’s adjusted EPS and operating income beats could indicate temporary timing effects, so the guidance cut may be more about phasing than fundamental demand deterioration.
Key entities
- companyBioMarin Pharmaceutical
NASDAQ-listed biotech issuer reporting Q3 2026 results and lowering full-year revenue and adjusted EPS guidance.
